MT7, a novel compound from a combinatorial library, arrests mitosis via inhibiting the polymerization of microtubules Zhixiang ZhangTao MengJian Ding PRECLINICAL STUDIES 25 August 2009 Pages: 715 - 728
NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth Maria PapaioannouSonja SchleichAria Baniahmad PRECLINICAL STUDIES 23 September 2009 Pages: 729 - 743
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model Lena E. FribergMarie SandströmMats O. Karlsson PRECLINICAL STUDIES 27 August 2009 Pages: 744 - 753
Synthesis, characterization and in vitro anti-tumor activities of novel 9-ethyl-9H-purine derivatives Raghu NingegowdaAmit GroverS. Nanjunda Swamy PRECLINICAL STUDIES 16 September 2009 Pages: 754 - 765
Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells Pay-Chin LeowQuan TianPui-Lai Rachel Ee PRECLINICAL STUDIES 03 September 2009 Pages: 766 - 782
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling Moyan LiuLili FuChanglin Mei PRECLINICAL STUDIES 16 September 2009 Pages: 783 - 790
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations In Hae ParkJin Young KimJi-Youn Han PRECLINICAL STUDIES 17 September 2009 Pages: 791 - 799
Antimetastatic activity of MONCPT in preclinical melanoma mice model Xiao-Chun YangChong-Xing TuBo Yang PRECLINICAL STUDIES 30 September 2009 Pages: 800 - 811
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification Subhasree Roy ChoudhurySurajit KarmakarSwapan K. Ray PRECLINICAL STUDIES 24 September 2009 Pages: 812 - 824
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis Alexander SchultzeSebastian DeckerWalter Fiedler PRECLINICAL STUDIES 26 September 2009 Pages: 825 - 833
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas Elisa StroppaAlexia BertuzziArmando Santoro PHASE I STUDIES 07 July 2009 Pages: 834 - 838
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials Nicolas PenelPierre LeblondJacques Bonneterre PHASE I STUDIES 16 September 2009 Pages: 839 - 843
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer Isamu OkamotoMasaki MiyazakiKazuhiko Nakagawa PHASE I STUDIES Open access 18 September 2009 Pages: 844 - 853
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium Halla S. NimeiriDeepti A. SinghHedy L. Kindler PHASE II STUDIES 11 August 2009 Pages: 854 - 858
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes Daniel ChanWee-Lee YeoSoo-Chin Lee PHASE II STUDIES 25 August 2009 Pages: 859 - 865
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate Kuniaki ShiraoToshirou NishidaAtsushi Ohtsu PHASE II STUDIES 03 September 2009 Pages: 866 - 875
New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells Maria Alessandra SantucciManuela ManciniSilvia Schenone SHORT REPORT 24 July 2009 Pages: 876 - 878
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus Christophe MassardKarim FizaziBernard Escudier SHORT REPORT 01 August 2009 Pages: 879 - 881
Painful cervical esophageal erosion in a patient with advanced colorectal cancer treated with bevacizumab Carlos Eduardo PaivaYara Cristina de Paiva MaiaMauro Masson Lerco SHORT REPORT 02 September 2009 Pages: 882 - 883
Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors Dana M. HartlCharles FertéJean-Charles Soria SHORT REPORT 16 September 2009 Pages: 884 - 886
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review Filippo BellatiChiara NapoletanoPierluigi Benedetti Panici SHORT REPORT 24 November 2009 Pages: 887 - 894
Erratum to: Antimetastatic activity of MONCPT in preclinical melanoma mice model Xiao-Chun YangChong-Xing TuBo Yang Erratum 12 June 2010 Pages: 895 - 895